FDA Updates Internal IDE Review Policy
This article was originally published in The Gray Sheet
The new standard operating procedures will allow the recently established clinical trials director to get involved with resolving rejected investigational device exemptions or IDEs approved with conditions after the first round of FDA review.
You may also be interested in...
CDRH Director Jeffrey Shuren discussed the device center’s two-year strategic priorities with “The Gray Sheet.” The center plans to rebalance pre-market and post-market data collection, when appropriate, and improve the processes for starting up clinical trials in the U.S.
All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.